Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Cholesterol Lowering and the Use of Healthcare Resources: Results of the Scandinavian Simvastatin Survival Study

Pedersen, Terje R., Kjekshus, John, Berg, Kåre, Olsson, Anders G., Wilhelmsen, Lars, Wedel, Hans, Pyörälä, Kalevi, Miettinen, Tatu, Haghfelt, Torben, Færgeman, Ole, Thorgeirsson, Gudmundur, Jönsson, Bengt, Schwartz, J. Sanford·1996·Circulation

Abstract

Background Advances in the treatment of cardiovascular disease have increased costs; annual cardiovascular healthcare expenditure in the United States currently exceeds $100 billion. Physicians and third-party payers need to assess the economic impact of treatments that reduce cardiovascular morbidity and mortality. Methods and Results The Scandinavian Simvastatin Survival Study is a randomized, double-blind, placebo-controlled trial in which simvastatin reduced the risk of death by 30% ( P =.0003) over the median follow-up period of 5.4 years in patients with previous myocardial infarction or stable angina pectoris as a result of a 42% reduction in the risk of coronary deaths ( P =.00001). In the present report, data prospectively collected from hospital admissions were analyzed to evaluate the impact of simvastatin on healthcare resource use and perform a cost-minimization analysis. In the placebo group (n=2223), there were 1905 hospitalizations (average duration, 7.9 days) for acute cardiovascular events or coronary revascularization procedures among 937 patients, whereas in the simvastatin group (n=2221), there were 1403 such hospitalizations (average duration, 7.1 days) among 720 patients (all differences, P <.0001). The corresponding number of hospital days was 15 089 and 9951 in the two groups, respectively (34% reduction, P <.0001). In the United States, the resulting reduction in hospitalization costs over the 5.4 years of the trial would be $3872 per patient, reducing the effective cost of simvastatin by 88% to $0.28 per day. Conclusions In addition to reducing mortality and morbidity in coronary heart disease patients, simvastatin markedly reduces use of hospital services, thus offsetting most of its cost.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.93.10.1796

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 197

Metadata

Authors
Pedersen, T. R., Kjekshus, J., Berg, K., Olsson, A. G., Wilhelmsen, L., Wedel, H., Pyörälä, K., Miettinen, T., Haghfelt, T., Færgeman, O., Thorgeirsson, G., Jönsson, B., & Schwartz, J. S.
Venue
Circulation
Published
1996-05-15
Volume
93
Issue
10
Pages
1796-1802
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1989206114
Cited by
197
References
2
FWCI
36.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholesterol Lowering and the Use of Healthcare Resources: Results of the Scandinavian Simvastatin Survival Study. https://app.cochat.ai/papers/10.1161/01.cir.93.10.1796
The paper
Pedersen, T. R., Kjekshus, J., Berg, K., Olsson, A. G., Wilhelmsen, L., Wedel, H., Pyörälä, K., Miettinen, T., Haghfelt, T., Færgeman, O., Thorgeirsson, G., Jönsson, B., & Schwartz, J. S. (1996). Cholesterol Lowering and the Use of Healthcare Resources: Results of the Scandinavian Simvastatin Survival Study. Circulation. https://doi.org/10.1161/01.cir.93.10.1796

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.